Nancy L. Boman
General Counsel presso ADICET BIO, INC.
Profilo
Nancy L.
Boman is currently the Chief Regulatory Officer & Senior Vice President at Adicet Bio, Inc. She previously worked as a Principal at Amgen, Inc., Genentech, Inc., and QLT, Inc. She also served as the SVP-Clinical Development & Regulatory Affairs at CTI BioPharma Corp.
from 2013 to 2016.
Additionally, she held positions as VP-Clinical Development & Regulatory Affairs at Acucela, Inc. and Senior Vice President-Regulatory Affairs at Lundbeck Seattle BioPharmaceuticals, Inc. She was also the Chief Regulatory Officer at Novartis Gene Therapies, Inc. and Encoded Therapeutics, Inc. Dr. Boman received her undergraduate and doctorate degrees from the University of British Columbia.
Posizioni attive di Nancy L. Boman
Società | Posizione | Inizio |
---|---|---|
ADICET BIO, INC. | General Counsel | 29/11/2022 |
Precedenti posizioni note di Nancy L. Boman
Società | Posizione | Fine |
---|---|---|
CTI BIOPHARMA CORP. | General Counsel | 01/01/2016 |
AVEXIS INC | General Counsel | - |
Encoded Therapeutics, Inc.
Encoded Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Encoded Therapeutics, Inc. operates as a biotechnology company that engages in the development of precision medicines and therapy for genetic disorders. It focuses on viral gene therapies. The company was founded by Kartik Ramamoorthi and Stephanie Tagliatela and is headquartered in South San Francisco, CA. | General Counsel | - |
ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Formazione di Nancy L. Boman
University of British Columbia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
AMGEN INC. | Health Technology |
ADICET BIO, INC. | Health Technology |
Aziende private | 7 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
CTI BioPharma Corp.
CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Acucela, Inc.
Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Encoded Therapeutics, Inc.
Encoded Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Encoded Therapeutics, Inc. operates as a biotechnology company that engages in the development of precision medicines and therapy for genetic disorders. It focuses on viral gene therapies. The company was founded by Kartik Ramamoorthi and Stephanie Tagliatela and is headquartered in South San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Nancy L. Boman